Swedish OrphanBiovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, […]

Visualizes CX bottlenecks and differentiation factors based on survey data collected from 108 leading companies across 20 industries transcosmos today announced the publication of its 10th anniversary report, Consumer to Business Communications Trend Survey 2025-2026. The findings show that as smartphone adoption continues to rise, consumers increasingly prioritize self-service options for usability and time efficiency.

(Paris:SAN), Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo The safety profile of tolebrutinib was consistent with previous studies Paris, December 15, 2025. Results

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis GlobeNewswire December 15, 2025 Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo

As the year-end holiday season approaches, digital travel platformAgoda reveals the most affordable domestic and international flight routes across Asia. The list offers travelers insights into the routes that could offer a chance to celebrate without breaking the bank. Based on bookings made from September 2025 onwards for departures between December 20-31, Agoda reveals Thailand

Huyett's investment in Swiss Turn manufacturing pays off as customers turn to the Company for custom fastening solutions. In recent years, Huyett has expanded its manufacturing capabilities with the addition of several state-of-the-art Swiss Turn machines, which deliver tighter tolerances and faster cycle times compared to traditional lathes. “As we expand our Swiss machining capability,

(Brussels:ARGX),(NASDAQ:ARGX), 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe

(Paris:SAN), Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed Paris, December 15, 2025. Sanofi anticipates that the review process for the ongoing US regulatory review of tolebrutinib in non-relapsing secondary progressive

(Brussels:IBAB), Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world's most renowned academic journals –

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease GlobeNewswire December 15, 2025 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3